About Us

BOARD OF DIRECTORS

Nicholas L. Teti, Jr.
Chairman of the Board and Chief Executive Officer

Nicholas Teti has served on the Board of Directors of Suneva since April 2009 and as Chairman since July 2010. He was previously CEO of Isolagen, Inc., a biotechnology company which develops emergent, novel skin and tissue rejuvenation technologies. From 2001 to 2006, Mr. Teti was President and Chief Executive Officer of Inamed Corporation, a healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles, and devices to treat severe and morbid obesity, including the LAP-BAND Adjustable Gastric Banding System. He served on the board of Inamed in 2001 and was Chairman of the Board from 2002 to 2006 through the Allergan acquisition. Prior to Inamed, Mr. Teti spent twenty-five years at DuPont and DuPont Merck where he held a number of senior management positions including President and CEO of DuPont Pharmaceuticals. He currently serves on the Board of Enteromedics.

Mr. Teti holds a B.A. in Economics and an M.B.A in Health Care Administration from St. Joseph's University in Philadelphia, PA.

Douglas Abel

Douglas Abel has served on Suneva Medical's Board of Directors since its inception in April 2009 and joined the management team in his current role in 2011. Mr. Abel brings over 20 years of aesthetics, dermatology, specialty pharmaceuticals, and medical device experience to Suneva. He was previously Senior Vice President and General Manager of Onset Dermatologics, an emerging leader in the development and commercialization of novel prescription products for the treatment of skin disorders. From 2004 to 2009, Mr. Abel was President and Chief Executive Officer of Manhattan Pharmaceuticals, Inc. a specialty healthcare company focused on developing and commercializing innovative treatments for underserved patient populations with a focus on skin care; and subsequently served as the Chairman of Manhattan's Board of Directors. Prior to joining Manhattan, Mr. Abel served as Vice President and Dermatology Business Unit Head for Biogen Idec. Mr. Abel spent over 12 years with Allergan were he held a number of positions including serving as a member of the pioneering BOTOX® teams in both Neurology and Aesthetics.

Mr. Abel holds a B.A. in Chemistry from Lafayette College in Easton, PA and an M.B.A. from Temple University in Philadelphia, PA.

Todd C. Davis
Vice Chairman

Todd Davis is a founder, Managing Director at Cowen Healthcare Royalty Partners. Previously, Mr. Davis was a partner at Paul Capital Partners, where he focused on leading royalty-related investments for the Paul Royalty Funds. Prior to that, Mr. Davis was a partner at Apax Partners, responsible for leading private equity investments in biopharmaceutical companies. Mr. Davis has extensive healthcare operating experience, having worked in business development and general management at Élan Pharmaceuticals and in sales and marketing at Abbott Laboratories. Mr. Davis has led or facilitated healthcare investments totaling over $600 million, of which approximately $400 million were structured royalty investments. Mr. Davis currently serves on the board of Ligand Pharmaceuticals and historically has served on the boards of several private and public companies.

Mr. Davis is a former U.S. naval officer and holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard Business School.

Clarke B. Futch, Esq.

Clarke Futch is a founder, Managing Director at Cowen Healthcare Royalty Partners. Mr. Futch has been a principal investor for eight years, having closed $700 million in royalty-related investments. Previously, Mr. Futch was a partner at Paul Capital Partners where he was responsible for sourcing, executing and managing investments for the Paul Royalty Funds; in addition, he was primarily responsible for two asset-backed note offerings. During his tenure at Paul Capital from 2001-2006, he served at various times on the investor relations, finance and secondary operating committees. Prior to that, Mr. Futch was a founding member of the healthcare group at Thomas Weisel Partners and a healthcare investment banker at Raymond James. Mr. Futch has substantial principal investing, capital markets, finance and international tax expertise, having closed over 125 transactions in his career. He has served on the boards of Prism Pharmaceuticals and Medical Carbon Research Institute.

Mr. Futch holds a B.A., magna cum laude, from Vanderbilt University and a J.D. from the University of Virginia School of Law.

Paul J. Hadden

Paul Hadden is a Vice President at Cowen Healthcare Royalty Partners. Prior to joining Cowen Healthcare, Mr. Hadden was a principal of The Frankel Group, a boutique healthcare management consulting firm based in New York. While at The Frankel Group from 2001-2007, Mr. Hadden advised biotechnology and pharmaceutical companies on business strategy, completing over 75 projects focused on commercial/market assessments, sales forecasting, marketing strategies and due diligence. Mr. Hadden was responsible for managing multiple teams of consultants and performing primary and secondary research. Prior to The Frankel Group, Mr. Hadden worked at New York-Presbyterian Hospital as a senior financial analyst providing financial planning support to the program development and clinical services division.

Mr. Hadden holds a B.A. from Yale College and an M.P.H. from the Yale School of Public Health.